CERo Therapeutics (NASDAQ:CERO) Upgraded at D. Boral Capital
D. Boral Capital upgraded shares of CERo Therapeutics (NASDAQ:CERO – Free Report) from a hold rating to a buy rating in a research report report published on Monday, Marketbeat Ratings reports. D. Boral Capital currently has $30.00 price target on the stock. CERO has been the subject of several other reports. Maxim Group assumed coverage […]
D. Boral Capital upgraded shares of CERo Therapeutics (NASDAQ:CERO – Free Report) from a hold rating to a buy rating in a research report report published on Monday, Marketbeat Ratings reports. D. Boral Capital currently has $30.00 price target on the stock. CERO has been the subject of several other reports. Maxim Group assumed coverage […]
